OncoMatch/Clinical Trials/NCT06190782
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
Is NCT06190782 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including PD-1 inhibitor+/- chemotherapy combined with local therapy and systemic therapy alone for esophageal squamous cell carcinoma.
Treatment: PD-1 inhibitor+/- chemotherapy combined with local therapy · systemic therapy alone — Patients with oligometastatic squamous cell carcinoma were enrolled and randomly assigned to receive either PD-1 inhibitor +/- chemotherapy combined with local therapy or PD-1 inhibitor +/- chemotherapy alone. The primary end point was progression-free survival (PFS). The secondary end points included overall survival, side effects and local control.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: pd-1 inhibitor
Exception: progression disease after pd-1 inhibitor treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify